Publications

We strongly believe in the value of scientific dissemination as an instrument of knowledge and progress. Since 2009, the results of our clinical trials have been published in leading sectorial journals and presented at several international conferences.

Publications in scientific journals

Nothing in life is to be feared, it is only to be understood. Now is the time to understand more, so that we may fear less.
Marie Curie

Oliva EN, Cuzzola M, Nobile F, et al. (2010).
Changes in RPS14 expression levels during lenalidomide treatment in Low-and Intermediate-1-risk myelodysplastic syndromes with chromosome 5q deletion. Eur J. Haematol, 85:231-5.
Go to original article

Oliva EN, Nobile F, Alimena G, et al. (2010). Darbepoetin For The Treatment Of Anemia Of Myelodysplastic Syndromes: Efficacy And Quality Of Life. Leukemia and Lymphoma, 51(6):1007-14.

Go to original article

Breccia M, Cannella L, Latagliata R, et al. (2011). Unexpected erythroid and cytogenetic responses after discontinuation of short course of lenalidomide due to severe skin rash in a 5q syndrome patient. J Clin Oncol, May 10;29(14): e 402-3.

Go to original article

Breccia M, Cannella L, Latagliata R, et al. (2011). Sudden acute leukemia transformation in a MDS patient with del (5q) in complete cytogenetic remission after lenalidomide. Leuk Res., 35, 690.

Go to original article

Cannella L, Latagliata R, Breccia M, et al. (2012). Very short-term lenalidomide treatment associated with durable resolution of anemia in a patient with myelodysplastic syndrome with chromosome 5q deletion. Ann Hematol, Feb; 91 (2):309-10.

Go to original article

Oliva EN, Cuzzola M, Poloni A, et al. (2013). Biological activity of lenalidomide in myelodysplastic sindromes with del5q: results of gene expression profiling from a multicenter phase II study. Ann Hematol., Jan;92(1):25-32.

Go to original article

Oliva EN, Latagliata R, Laganà C, et al. (2013). Lenalidomide in Low-and intermediate-1 IPSS risk myelodysplastic sindromes with del(5q): an Italian phase II trial of health-related quality of life, safety, and efficacy. Leuk Linphoma., Nov;54(11):2458-65.

Go to original article

Oliva EN, Lauseker M, Aloe Spiriti MA, at al. (2015). Early lenalidomide treatment for low and intermediate-1 International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependence. Cancer Med., Dec; 4(12):1789-97.

Go to original article

Oliva EN, Alati C, Santini V, et al. (2017). Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial. Lancet Haematol., Mar;4(3): e127-e136. doi: 10.1016/S2352-3026(17)30012-1.

Go to original article

Oliva EN, Latagliata R, Sabattini E, et al. (2021) Accuracy of bone marrow histochemical TP53 expression compared to the detection of TP53 somatic mutations in patients with myelodysplastic syndromes harbouring a del5q cytogenetic abnormality. Am J Blood Res., 11(4): 417–426

Go to original article

Presentations at conferences

2009

Oliva EN, Cuzzola M, Iacopino P, et al. (2009). Gene expression patterns in MDS with del5q before and during Lenalidomide treatment. MDS International Symposium, Patrasso, Grecia, maggio 2009. Leuk Res, supplement, 2009.

Oliva EN, Latagliata R, Morabito F, et al. (2009). Lenalidomide for the treatment of Low- and Int-1-Risk MDS with Del(5q): efficacy and quality of life study. 51th ASH Annual Meeting; Blood 2009 114:2763 ISSN: 1528-0020; New Orleans (Louisiana) USA, 5-8 dicembre 2009 

 Oliva EN; Cuzzola M, Latagliata R, et al. (2009). Gene expression changes in bone marrow of MDS patients with Del(5q) during Lenalidomide treatment. 51th ASH Annual Meeting; Blood 2009 114:2622 ISSN: 1528-0020; New Orleans (Louisiana) USA, 5-8 dicembre 2009

2011

Oliva EN, Nobile F, Alimena G, et al. (2011). Quality of life in elderly patients with Acute Myeloid Leukemia: patients may be more accurate than physicians. 16th Congresso EHA; Haematologica May 2011 96: 696-702; Londra, UK, 9-12 giugno 2011

Oliva EN, Latagliata R, Aloe Spiriti MA, et al. (2011). Clinically meaningful responses in low risk MDS patients with del5q treated with lenalidomide: quality of life and cardiac changes. Leukemia Research 35 (2011) S27–S142. 11th Simposio Internazionale sulle Sindromi Mielodisplastiche (MDS), 18-21 maggio 2011, Edinburgo, UK

Oliva EN, Nobile F, Alimena G, et al. (2011). Quality of life in elderly patients with acute myeloid leukemia: patients may be more accurate than physicians. Haematologica. 2011, maggio; 96(5):696-702  

2012

Oliva EN; Santini V, Zini G, et al. (2012). Efficacy and safety of Eltrombopag for the treatment of thrombocytopenia of low and intermediate-1 IPSS risk Myelodysplastic Syndromes: interim analysis of a prospective, randomized, single-blind, placebo-controlled trial (EQoL-MDS). 54thASH Annual Meeting. Blood, vol. 120:923, ISSN: 1528-0020, Atalanta (Georgia) USA, 9-12 dicembre 2012

2013

Oliva EN, Santini V, Zini G, et al. (2013). Eltrombopag for the treatment of Low and Intermediate -1 IPSS Risk Myelodyslastic Syndromes: results of a prospective, randomized, trial. 18th Congresso EHA; Haematologica June 2013 98: (s1); Stoccolma, Svezia, 13-16 giugno 2013  

Oliva EN, Santarone S, Leoni P, et al. (2013). A randomized open-label study to evaluate the efficacy of Azacitidine for post-remission therapy of Acute Myeloid Leukemia in elderly patients (QoLESS AZA-AMLE). 55th ASH Annual Meeting; Blood 2013 122:3967 ISSN: 1528-0020; New Orleans (Louisiana)USA, 7-10 dicembre 2013

2014

Oliva EN, Lauseker M, Aloe Spiriti MA, et al. (2014). Clinical benefit of Lenalidomide treatment for Low and Intermediate -1 IPSS Risk Myelodysplastic Syndromes with Del(5q) before transfusion dependence. 19th Congresso EHA; S1331; 99(s1) Haematologica 2014. Milano, Italia, giugno12-15 2014 

Oliva EN, Alati C, Salutari P, et al. (2014). Azacitidine as post-remission therapy in elderly patients with Acute Myeloid Leukemia significantly prolongs disease-free survival: interim results from a prospective, randomized, open-label, phase III multicenter trial. 56th ASH Annual Meeting Blood (2014) Poster 124 (21): 2299. San Francisco (California) USA, 6-9 dicembre 2014 

2015

Oliva EN, Santini V, Alati C, et a. (2015). Quality of life in patients with lower risk Myelodysplastic Syndromes with severe thrombocytopenia treated with Eltrombopag: Interim results of a randomized, placebo controlled prospective trial. 20th Congresso EHA; Haematologica vol. 100 ISSN: 0390-6078; Vienna, Austria, 11-14 giugno 2015

Oliva EN, Santini V, Alati C, et al. (2015). Eltrombopag for the treatment of thrombocytopenia of low and intermediate-1 IPSS risk Myelodysplastic Syndromes: interim results on efficacy, safety and quality of life of an international, multicenter prospective, randomized, trial. 57th ASH Annual Meeting; Blood 2015 126:91 ISSN: 1528-0020¸ Orlando (Florida) USA, 5 – 8 dicembre 2015 

 Oliva EN, Salutari P, Candoni A, et al. (2015). Quality of life in elderly patients with Acute Myeloid Leukemia undergoing induction chemotherapy. 57th ASH Annual Meeting; Blood 2015 126:2120   ISSN: 1528-0020; Orlando (Florida) USA, 5 – 8 dicembre 2015

Oliva EN, Santini V, Alati C, et al. (2015). Quality of life in patients with lower risk Myelodysplastic Syndromes with severe thrombocytopenia treated with Eltrombopag: interim results of a randomized, placebo controlled prospective trial. 20th Congresso EHA; Haematologica vol. 100 ISSN: 0390-6078; Vienna, Austria, 11-14 giugno 2015 

Oliva EN, Santini V, Alati C, et al. (2015). Eltrombopag for the treatment of thrombocytopenia of low and intermediate-1 IPSS risk Myelodysplastic Syndromes: interim results on efficacy, safety and quality of life of an international, multicenter prospective, randomized, trial.  In: 57th ASH Annual Meeting; Blood 2015 126:91   ISSN: 1528-0020; Orlando (Florida) USA, 5 -8 dicembre 2015

2016

Cuzzola M, Alati C, Di Bartolomeo P, et al. (2016). Biological markers of relapse in elderly patients with AML in CR after induction-consolidation chemotherapy and manteinance with 5-Azacitidine. 21th Congresso EHA; EHA Library. Jun 9, 2016; Poster 132455; E906. Copenhagen, Danimarca, 9-12 giugno 2016 

2018

Oliva EN; Martino B, Salutari P, et al. (2018). Randomized open-label, phase III multicenter trial to evaluate Azacitidine post -remission therapy in elderly patients with Acute Myeloid Leukemia. 23th Congresso EHA; EHA Learning Center. OLIVA E. Jun 16, 2018; 215308; Stoccolma, Svezia, 14-17 giugno 2016

Di Rocco M, Cappellini MA, Carubbi F, et al. (2018). Observational study to develop treatment- related patient reported outcome measure in Gaucher disease (QOL-ONE PRO 1G). 23th Congresso EHA; EHA Learning Center. OLIVA E. Jun 14, 2018; 216144¸ Abstract: PB2398; Stoccolma, Svezia, 14-17 giugno 2016

2019

Oliva EN, Candoni A, Salutari P, et al. (2019). Azacitidine for post remission therapy in elderly patients with Acute Myeloid Leukemia: final results of the Qoless AZA-AMLE randomized trial. 61th ASH Annual Meeting; Orlando (Florida), Usa, 7-10, dicembre 2019

 Oliva EN, Alati C, Santini V, et al. (2019). Long term effects of Eltrombopag treatment versus placebo for low-risk Myelodysplastic Syndromes with thrombocytopenia (EQoL-MDS): interim results of a single-blind, randomized, controlled, phase 2 superiority trial. 61th ASH Annual Meeting; Orlando (Florida), Usa, 7-10, dicembre 2019

2021

Oliva EN, Mammi’ C, Cuzzola M, et al. (2021). NGS evaluation of the Eqol-MDS trial: preliminary analysis of Eltrombopag for thrombocytopenia of low-risk MDS. 63th ASH Annual Meeting; Atlanta, Georgia, dicembre 11-14 2021 

2022

Urciuoli E, Di Bona E, Greve S, et al. (2022). Observational study to evaluate patient – reported outcomes in Paroxysmal Nocturnal Hemoglobinuria. 26th Congresso EHA. Poster Quality of life, palliative care, ethics and health economics EHA-2996. 26th Congresso EHA; Vienna, Austria, 9-12 giugno 2022

Oliva EN, Salutari P, Di Raimondo F, et al. (2022) Final results of the QoLESS AZA–AMLE randomized trial to evaluate the efficacy of 5- Aza for post-remission therapy of Acute Myeloid Leukemia in elderly patients. Poster 04. Acute myeloid leukemia – Clinical EHA; 26th Congresso EHA; Vienna, Austria, 9-12 giugno 2022

Help us improve our service

Donate now

Supporting innovation to improve the quality of life in patients suffering from hematological diseases.

Address

Via C. Quattrone n°8 Pellaro
Reggio Calabria 89134

Phone

+39 329 869 9514

E-mail

info@qol-one.org